World Health Organization Issues Warning Over Acute Shortage of Obesity Injections
Fewer than one in 10 people eligible to benefit from GLP-1 drugs including Wegovy have access to them, caution the WHO as it releases its inaugural guidance on the drugs.
With in excess of 1,000,000,000 people worldwide now classified as obese, it is urging increased and just access to this class of drugs.
According to projections, more than two billion could be living with obesity by 2030 without intervention.
"Our latest guidance affirms that obesity is a lifelong illness that can be addressed with thorough and lifelong care," said WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and logistical bottlenecks are major obstacles to broad access to the injections that can assist patients in reducing substantial body mass, explains the organization.
Skinny Jab Supply Crisis
Despite the present best projected scenario, the supply of such drugs would only suffice for approximately 100 million people – less than 10% of eligible patients, as stated by the WHO.
The guideline urges nations and manufacturers to widen availability, by measures including licensing agreements.
The intellectual property rights on semaglutide – the core ingredient of Novo Nordisk's Wegovy – is due to expire in multiple countries in 2026.
How Weight-Loss Jabs Operate
GLP-1 drugs replicate a biological compound to delay gastric emptying, reduce hunger and enhance satiety so users reduce food intake.
Individuals usually start to lose weight in the initial weeks of starting on the once-weekly jabs.
Research points to people may see weight return after a year of stopping the treatment, when their typical hunger come back.
To be carrying excess weight elevates your chance for experiencing health problems, such as type 2 diabetes, cardiovascular issues, stroke, and specific malignancies.
Excess weight impacts individuals in countries worldwide and was responsible for millions of fatalities worldwide in 2024, per the WHO.
